AgingResearch.NewsJoin free

Keros Therapeutics

CompanyUnited StatesFounded 2015

Wikidata

Keros Therapeutics develops one asset, in phase 2 (Rinvatercept in Duchenne muscular dystrophy). Mostly protein or enzyme acting on ACVR2A and ACVR2B; based in the United States, founded in 2015.

1
Asset
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

1

  • Rinvatercept

    Modified activin receptor type II ligand-trap protein

    Phase 2, Protein or enzyme, ACVR2A, ACVR2B, Duchenne muscular dystrophy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Similar companies4

Intelligence